Exploring the Occurrence Mechanism and Early-Warning Model of Phlebitis Induced by Aescinate Based on Metabolomics in Cerebral Infarction Patients
Zhipeng Wang,You Yin,Yuhui Mu,Lili Cui,Xinhua Song,Jianhua Zhuang,Shouhong Gao,Xia Tao,Wansheng Chen
DOI: https://doi.org/10.2147/jir.s436846
IF: 4.5
2024-01-18
Journal of Inflammation Research
Abstract:Zhipeng Wang, 1, &ast You Yin, 2, &ast Yuhui Mu, 1, 3, &ast Lili Cui, 1 Xinhua Song, 1 Jianhua Zhuang, 2 Shouhong Gao, 1 Xia Tao, 1 Wansheng Chen 1 1 Department of Pharmacy, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai, 200003, People's Republic of China; 2 Department of Neurology, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai, 200003, People's Republic of China; 3 College of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, 650500, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianhua Zhuang, Department of Neurology, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), No. 415, Fengyang Road, Shanghai, 200003, People's Republic of China, Email Xia Tao, Department of Pharmacy, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), No. 415, Fengyang Road, Shanghai, 200003, People's Republic of China, Tel/Fax +86– 21– 81886191, Email Objective: This study aims to explore the mechanism underlying the induction of phlebitis by aescinate and create an early-warning model of phlebitis based on metabolomics. Methods: Patients with cerebral infarction enrolled had been treated with aescinate. Plasma samples were collected either before administration of aescinate, upon the occurrence of phlebitis, or at the end of treatment. Non-targeted metabolomics and targeted amino acid metabolomics were carried out to analyze metabolic profiles and quantify the metabolites. Results: Untargeted metabolomics revealed six differential metabolites in baseline samples versus post-treatment samples and four differential metabolites in baseline samples from patients with or without phlebitis. Pathways of these differential metabolites were mainly enriched in amino acid metabolism. Ten differential amino acids with a VIP value of > 1 were identified in the baseline samples, enabling us to distinguish between patients with or without phlebitis. A logistic regression model was constructed (AUC 0.825) for early warning of phlebitis of grade 2 or higher. Conclusion: The occurrence of aescinate-induced phlebitis, which can be predicted early during onset, may be associated with perturbations of the endogenous metabolic profile, especially the metabolism of amino acids. Keywords: aescinate, diagnostic model, mechanism, metabolomics, phlebitis Graphical Aescinate is a bioactive compound extracted from horse chestnut ( Aesculus hippocastanum ), a plant that is widely distributed throughout the world. 1 Aescinate A and B are the main components of sodium aescinate formulations that have pharmacological efficacy benefits. 2 It has anti-edema and anti-inflammatory properties and is useful for treating cerebral dysfunction and venous reflux diseases induced by edema, and it stimulates the secretion of prostaglandin 2 (PGE2) from the vascular wall, 3,4 inhibits PGE1 release, and removes free radicals. 5,6 Aescinate also promotes blood reflux. 7–9 Clinically, aescinate is predominantly administered intravenously, with the main side effect being peripheral phlebitis. The medicine may interact with inflammatory cells and necrotic endothelial cells, resulting in phlebitis. 10,11 Aescinate has a critical role in controlling edema after surgery, but more than 70% patients develop phlebitis to varying degrees at 3 to 5 days after drug administration. 12 Some studies have reported that the concentration of aescinate, pH value, the carrier solution, time of infusion, osmolality, the type of peripheral intravenous catheter, and rate of infusion are critical factors inducing phlebitis, 13,14 and improving these factors is beneficial to some extent. We previously quantified aescinate A and B in human plasma, but the results revealed that the incidence and grading of phlebitis were not associated with the in vivo exposure of aescinate A and aescinate B. 13 Therefore, we concluded that additional information must be gathered concerning the in vivo effectiveness of administering aescinate in the clinical setting. In this regard, we chose to utilize metabolomics for additional studies of aescinate, as this research tool constitutes a powerful method for studying changes in complex systems. Metabolomics can generate both qualitative and quantitative data for small-molecule metabolites, which allows comprehensive analysi -Abstract Truncated-
immunology